TY - JOUR
T1 - New antiepileptic drugs currently in clinical trials
T2 - Is there a strategy in their development?
AU - Bialer, Meir
PY - 2002
Y1 - 2002
N2 - In designing and developing antiepileptic drugs (AEDs), attention should be paid to the desirable pharmacokinetic properties of potential new agents so that molecules are designed to achieve the desired pharmacodynamic and pharmacokinetic profiles. A review of current compounds in development or in clinical trials shows that several promising agents have incorporated pharmacokinetic-based design into their development process. This is particularly true for new AEDs that are second-generation or follow-up compounds of existing AEDs.
AB - In designing and developing antiepileptic drugs (AEDs), attention should be paid to the desirable pharmacokinetic properties of potential new agents so that molecules are designed to achieve the desired pharmacodynamic and pharmacokinetic profiles. A review of current compounds in development or in clinical trials shows that several promising agents have incorporated pharmacokinetic-based design into their development process. This is particularly true for new AEDs that are second-generation or follow-up compounds of existing AEDs.
KW - New antiepileptic drugs
KW - Pharmacodynamic-based drug design
KW - Pharmacokinetic-based drug design
KW - Second-generation antiepileptic drugs
UR - http://www.scopus.com/inward/record.url?scp=0036146487&partnerID=8YFLogxK
U2 - 10.1097/00007691-200202000-00015
DO - 10.1097/00007691-200202000-00015
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 11805728
AN - SCOPUS:0036146487
SN - 0163-4356
VL - 24
SP - 85
EP - 90
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 1
ER -